Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Sucampo Pharmaceuticals SCMP

Healthcare Drug Manufacturers - Specialty & Generic

"Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development... see more

Add To Watchlist

Recent & Breaking News (NDAQ:SCMP)

Sucampo and National Cherry Blossom Festival Announce Sucampo as Host and 'Step Into Spring' Program Sponsor for 2014

GlobeNewswire March 4, 2014

Sucampo Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2013 Financial and Operating Results

GlobeNewswire February 26, 2014

Sucampo Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Results and Operating Highlights Teleconference and Webcast

GlobeNewswire February 12, 2014

Sucampo Names Peter Greenleaf Chief Executive Officer

GlobeNewswire February 10, 2014

All Physicians in Switzerland Are Now Able to Prescribe Sucampo's AMITIZA(R) for Chronic Idiopathic Constipation

Globe Newswire February 6, 2014

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2014 Leerink Global Healthcare Conference

Globe Newswire February 5, 2014

Sucampo Reports Results from Phase 2a Study of Intravenous Ion Channel Activator for Lumbar Spinal Stenosis

Globe Newswire December 23, 2013

Sucampo and Takeda Initiate Global Pivotal Phase 3 Program of Lubiprostone in Pediatric Functional Constipation

Globe Newswire December 17, 2013

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2013 Credit Suisse Healthcare Conference

Globe Newswire November 6, 2013

Numab Reacquires Advanced Compound from Sucampo

Business Wire October 29, 2013

Sucampo and Takeda Initiate Pivotal Trial of Lubiprostone Liquid Formulation in Adults With Chronic Idiopathic Constipation

Globe Newswire October 23, 2013

Sucampo Pharmaceuticals Announces Third Quarter and Nine Months 2013 Results and Operating Highlights Teleconference and Webcast

Globe Newswire October 22, 2013

Sucampo Announces Completion of Patient Enrollment in a Phase 3 Clinical Study of Unoprostone Isopropyl for Retinitis Pigmentosa

Globe Newswire October 21, 2013

Sucampo Announces Presentation of Results on AMITIZA(R) (lubiprostone) in Opioid-Induced Constipation at Two Upcoming Scientific Conferences

Globe Newswire October 11, 2013

Sucampo Announces Presentation of Results on Lubiprostone in Pediatric Functional Constipation at NASPGHAN 2013

Globe Newswire October 10, 2013

Clinical Data Show That Lubiprostone is Efficacious and Well Tolerated in Children and Adolescents With Functional Constipation

Globe Newswire October 8, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on CGIX, RMTI, SCMP and VTUS

Accesswire September 30, 2013

Sucampo to Present Data on AMITIZA(R) (Lubiprostone) in Opioid-Induced Constipation at 24th Annual AAPM Meeting

Globe Newswire September 27, 2013

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at BioCentury(R) NewsMakers in the Biotech Industry 2013 Conference

Globe Newswire September 20, 2013

Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the Swiss Society of Gastroenterology

Globe Newswire September 12, 2013